Institut fuer Klinische Transfusionsmedizin und Immungenetik Ulm gGmbH
- Address
- lock Available on a paid plan
Immune System Diseases
At Institut fuer Klinische Transfusionsmedizin und Immungenetik Ulm gGmbH, clinical research is centered on immune system diseases, with a strong focus on Paroxysmal Nocturnal Hemoglobinuria. The studies are designed to better understand this rare condition and to assess new treatment options that may improve long-term disease control and patient well-being.
- Research on Paroxysmal Nocturnal Hemoglobinuria and related immune-mediated blood disorders
- Evaluation of the safety and tolerability of new therapies for long-term use
- Clinical work aimed at improving treatment effectiveness for patients with chronic immune system conditions
With 8 trials and 96 investigators involved, the site in Ulm contributes to advancing care for rare hematologic and immunologic diseases through focused clinical evaluation.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 24 therapeutic areas and 15 of 531 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 519 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 120 by active trials.
- 1Novartis Pharma AG14active
lock +119 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1F. Hoffmann-La Roche AG34trials
lock +73 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Institut fuer Klinische Transfusionsmedizin und Immungenetik Ulm gGmbH
lock Showing 1 of 487 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| 2022-501606-35-00 – Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRα-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA). | AbbVie Deutschland GmbH & Co. KG | Phase I | Not Yet Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 531 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cyclophosphamide | 30 | Unknown | 2014-03-27 | 2026-06-08 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.